Dr Chan Hiok Hong

Dr Chan Hiok Hong is a Consultant at the Singapore National Eye Centre (SNEC), specialising in Medical Retina and Cataract & Comprehensive Ophthalmology. 

He graduated from the Yong Loo Lin School of Medicine, National University of Singapore (NUS), with a Bachelor of Medicine and Bachelor of Surgery (MBBS) in 2013. During medical school, he was awarded the Gold Medal and Book Prize in Ophthalmology. He completed his residency training at SNEC, earning his Master of Medicine (Ophthalmology) in 2019. In 2021, he achieved specialist accreditation in Ophthalmology and became a Fellow of the Academy of Medicine, Singapore. 

Dr Chan pursued advanced clinical subspecialty fellowship training in Medical Retina at SNEC in 2023. In 2024, he was awarded the prestigious Health Manpower Development Plan (HMDP) Award for further fellowship training at the University of California, Los Angeles (UCLA) Jules Stein Eye Institute under Professor David Sarraf. This experience provided him with valuable expertise in multi-modal ocular imaging systems and exposure to retinal drug toxicities. 

He has a clinical interest in cataract surgery and a research interest in retinal imaging, with multiple publications in peer-reviewed journals. He currently leads the PRISM (Prospective Retinal Imaging of Systemic Medications) study initiative and helms the newly established Retinal Toxicity Clinic at SNEC, aimed at advancing screening and management of systemic drug-induced retinal diseases. In 2025, Dr Chan was appointed Clinical Director of the Ocular Imaging Service at SNEC, where he oversees service development, workflow optimization, imaging innovation, and cross-disciplinary collaboration. He also serves as the Deputy Program Director for Fellowships at SNEC, supporting training and mentorship of future ophthalmologists. 

Beyond his clinical and academic achievements, Dr. Chan has taken on significant leadership and administrative roles. He served as Lead Resident (2020), Senior Lead Resident (2021), and was appointed Chief Resident of SNEC (2022). His contributions to residency training and clinical excellence have earned him multiple accolades. 

Dr Chan has received numerous awards in recognition of his contributions to healthcare, research, and leadership. In 2024, he was honored with the Health Manpower Development Plan Award for his fellowship at UCLA and received both the 10 Years Long Service Award and the Silver Award at the Singapore Health Quality Service Awards from SingHealth. In 2023, he was awarded the COVID-19 Resilience Medal in recognition of his efforts during the pandemic. His dedication to patient care was also acknowledged with the Hero Award at the Singapore Health Quality Service Awards in 2021. He was recognized as an exceptional resident with the Outstanding Resident Award under the SingHealth Excels (RiSE) Awards in 2020. Earlier in his career, he won Best Poster (Junior Category) at the National Ophthalmology Research Day in 2015. 

Dr Chan believes in evidence-based and patient-centric approach to clinical care. His current practice includes medical retina, cataract surgery and comprehensive ophthalmology.

• FAMS (2021)·     
• M Med(Ophth) (2019)
• MBBS (2013)

• Member, Singapore Society of Ophthalmology (SSO)
• Member, European Society of Retinal Specialist (EURETINA)

• Health Manpower Development Plan Award – Fellowship at UCLA, Jules Stein Eye Institute (2024)
• 10 years Long Service Award, SingHealth (2024)
• Silver Award, Singapore Health Quality Service Awards, SingHealth (2024)
• COVID-19 Resilience Medal (2023)
• Hero Award (2021)
• Outstanding Resident Award (Singhealth RiSE award) (2020)
• Chief Army Medical Officer Medal of Commendation (2016) 
• Winner of Best Poster – Junior Category of National Ophthalmology Research Round (2015)
• Gold Medal and Book prize in Ophthalmology (NUS Academic award) (2013)

1. Type 4 Macular Neovascularization (NV): A New Member of the Optical Coherence Tomography (OCT) Classification of NV Age-Related Macular Degeneration (AMD) Chan HH, Feo A, Cabral D, Bousquet E, Popovic MM, Marin AI, Quarta A, El-Haig WM, Chong Teo KY, Tan ACS, Gemmy Cheung CM, Querques G, Govetto A, Romano MR, Mastropasqua R, Sadda SR, Sarraf D. Retina. 2025 Sep 3. DOI: 10.1097/IAE.0000000000004664, PMID: 40924919

2. Incidence of Visual Loss in Patients with Diabetic Macular Ischemia (DMI): A 1-year Prospective Study, Gilead N, Chong YJ, Yamaguchi TCN, Chan HH, Fenner BJ, Ibrahim FI, Sun C, Sivaprasad S, Gemmy Cheung CM. Retina. 2025 May 6. DOI: 10.1097/IAE.0000000000004483PMID: 40334126

3. Vitelliform Lesions Associated with Angioid Streaks: Long-Term Follow-Up of a Rarely Described Phenotype Feo A, Bousquet E, Faes L, Ramtohul P, Sacconi R, Rissotto F, Boscia G, Abraham N, Lior TE, Faghihi S, Popovic MM, Chan HH, Gemmy Cheung CM, Fouad Y, Cabral D, Govetto A, Romano MR, Querques G, Farvo SRS, Freund KB, Sarraf D. Retina. 2025 Apr 11. DOI: 10.1097/IAE.0000000000004485, PMID: 40239167

4. Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial, Chong YJ, Teo KYC, Wong W, Tan ACS, Su X, Gilead N, Chan HH, Ibrahim F, Fenner B, Ong C, Sun C, Sim S, Chee C, Chakravarthy U, Cheung CMG.JAMA Ophthalmol. 2025 May 1;143(5):393-399. DOI: 10.1001/jamaophthalmol.2025.0250PMID: 40146166

5. Pneumatic Displacement of Submacular Haemorrhage Secondary to Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Sim SS, Cheong KX, Chan HH, Choo JQH, Tsai ASH, Lee SY, Yeo IYS, Cheung CMG, Teo KYC. Eye (Lond). 2024 Dec;38(17):3374-3381. DOI: 10.1038/s41433-024-03318-4PMID: 39294233

6. Initial Experiences of Switching to Faricimab for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in an Asian Population; Ibrahim FNI, Teo KYC, Tan TE, Chan HH, Chandrasekaran PR, Lee SY, Tan ACS, Mathur R, Chan CM, Sim SS, Tan GSW, Yeo IYS, Cheung CMG. Front Ophthalmol (Lausanne). 2024 Jan 11;3:1346322.DOI: 10.3389/fopht.2023.1346322,PMID:38982998

7. A Case of Secondary Multiple Evanescent White Dot Syndrome in a Patient with Preexisting Wet Age-Related Macular Degeneration.Chandrasekaran PR, Chan HH, Tan TE, Ibrahim FNI, Zhao J, Teo KYC. Am J Ophthalmol Case Rep. 2024 Mar 7;34:102016. DOI: 10.1016/j.ajoc.2024.102016,PMID: 38559365

8. Atypical Bilateral Extensive Retinal Venous Beading, Telangiectasia, and Ischemia, Sun C, Chan HH, Sim SSKP, Cheung CMG. Can J Ophthalmol. 2024 Aug;59(4):e419-e422.
DOI: 10.1016/j.jcjo.2024.02.006. PMID: 38462233

9. The Economic Burden of Inherited Retinal Disease in Singapore: A Prevalence-Based Cost-of-Illness Study. Chay J, Tang RWC, Tan TE, Chan CM, Mathur R, Lee BJH, Chan HH, Sim SSKP, Farooqui S, Teo KYC, Fenwick EK, Lamoureux EL, Cheung CMG, Fenner BJ. Eye (Lond). 2023 Dec;37(18):3827-3833. DOI: 10.1038/s41433-023-02624-7,PMID: 37301937

10. Positive-Charge Tuned Gelatin Hydrogel-siSPARC Injectable for siRNA Anti-Scarring Therapy in Post-Glaucoma Filtration Surgery. Chun YY, Yap ZL, Seet LF, Chan HH, Toh LZ, Chu SWL, Lee YS, Wong TT, Tan TTY. Sci Rep. 2021 Jan 14;11(1):1470. DOI: 10.1038/s41598-020-80542-4.PMID: 33446775

11. Repeatability of Tear Meniscus Evaluation Using Spectral-Domain Cirrus® HD-OCT and Time-Domain Visante® OCT. Chan HH, Zhao Y, Tun TA, Tong L. Cont Lens Anterior Eye. 2015 Oct;38(5):368-372. DOI: 10.1016/j.clae.2015.04.002.PMID: 25956571

12. A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes. Chan HH, Wong TT, Lamoureux E, Perera S. J Glaucoma. 2015 Sep;24(7):485-492. DOI: 10.1097/IJG.0000000000000197. PMID: 25580892